blog

What Would Be The Tenacity Of The Interventional Pulmonology Market In The Next 10 Years?

Interventional pulmonology is an area of pulmonary medicine that deals specifically with minimally invasive endoscopic and percutaneous procedures for the diagnosis and treatment of neoplastic as well as non-neoplastic diseases of the airways, lungs, and pleura. Rise in the number of COPD cases across the world is expected to boost demand over the coming years. Need for faster recovery time and reduced pain during procedures and surgeries for respiratory disorders has strengthened the market. Leading manufacturers of interventional pulmonology devices are focusing on geographical expansion to increase revenue and add new repair and service centers in emerging countries through the acquisition of local players.

Various awareness programs have been initiated by healthcare providers and health organizations/societies such as environmental programs, medication maintenance programs, and online education programs for public and healthcare professionals across the globe to control asthma, COPD, and other respiratory diseases. Major companies such as Boston Scientific Corporation, Olympus Corporation, and FUJIFILM Corporation, besides others, are focused on spreading awareness regarding respiratory diseases.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/12544

Companies covered in Interventional Pulmonology Market Report

Medtronic Plc

Boston Scientific Corporation

Olympus Corporation

FUJIFILM Corporation

Becton, Dickinson and Company

Smiths Group Plc

Cook Medical

Vygon

Clarus Medical LLC

Huger Medical Instrument Co. Ltd

Taewoong Medical Co. Ltd.

Shanghai AoHua Photoelectricity Endoscope Co., Ltd

Karl Storz

Richard Wolf Corporation

PENTAX Medical

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/12544

As per Persistence Market Research analysis, the global interventional pulmonology market is expected to exhibit a CAGR of more than 4% over the forecast period (2021 – 2031).

Key Takeaways from Study

IP diagnostic devices are expected to hold maximum revenue share under products.

Lung cancer is projected to be the dominant segment among indications, in terms of revenue. The segment accounted for 26.6% share in 2020.

The U.S., followed by Europe, is expected to hold substantial revenue share in the global interventional pulmonology market.

Emerging economies such as China, India, Brazil, Mexico, and South Africa have a large COPD patient pool, and rising disposable income of patients with increased healthcare expenditure would encourage interventional pulmonology device manufacturers to enter these markets.

The interventional pulmonology space faced adverse effects due to...

Do you already have an account? Log in here

Posted in: USA/Canada

Join the discussion

0 comments

To read and post comments you need to login or register